Blood pressure medicine starts with l
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Blood Pressure Medicine Starting with "L"
L-Arginine Supplementation and Blood Pressure Reduction
L-Arginine as a Blood Pressure Lowering Agent
L-arginine, an amino acid and a substrate of nitric oxide synthase, has been studied for its potential to lower blood pressure. A meta-analysis of randomized, double-blind, placebo-controlled trials involving 387 participants demonstrated that oral L-arginine supplementation significantly reduces both systolic and diastolic blood pressure. Specifically, L-arginine lowered systolic blood pressure by an average of 5.39 mm Hg and diastolic blood pressure by 2.66 mm Hg compared to placebo. These findings suggest that L-arginine can be an effective supplement for managing hypertension.
Mechanism of Action
The blood pressure-lowering effect of L-arginine is attributed to its role as a precursor to nitric oxide, a vasodilator that helps relax blood vessels, thereby reducing total peripheral resistance and lowering blood pressure. This mechanism is supported by studies showing that inhibition of nitric oxide synthesis increases blood pressure, indicating the critical role of nitric oxide in maintaining vascular health.
Quadruple Combination Therapy Including L-Arginine
Quadpill Strategy for Hypertension Management
A novel approach to hypertension management involves the use of a single pill containing a combination of four blood pressure medications at ultra-low doses. The QUARTET trial compared this quadpill strategy to standard monotherapy in patients with hypertension. The quadpill included irbesartan, amlodipine, indapamide, and bisoprolol, but did not specifically include L-arginine. However, the concept of combining multiple agents at low doses aligns with the strategy of using L-arginine to enhance nitric oxide production and improve blood pressure control.
Efficacy and Safety
The QUARTET trial found that the quadpill strategy was more effective in lowering systolic blood pressure and achieving blood pressure control compared to standard monotherapy. At 12 weeks, the intervention group had a significantly lower systolic blood pressure by 6.9 mm Hg and higher blood pressure control rates (76% vs. 58%) compared to the control group. This approach also maintained its efficacy over 52 weeks, with sustained lower systolic blood pressure and higher control rates.
Conclusion
L-arginine supplementation has been shown to significantly lower blood pressure by enhancing nitric oxide production, which relaxes blood vessels and reduces peripheral resistance. Additionally, innovative strategies like the quadpill, although not including L-arginine, demonstrate the potential benefits of combining multiple agents to achieve better blood pressure control. These findings highlight the importance of exploring various therapeutic options, including L-arginine, to effectively manage hypertension.
Sources and full results
Most relevant research papers on this topic